Shionogi

Shionogi’s flu drug wins green light in Japan, but U.S. approval not likely until 2019
Shionogi’s flu drug wins green light in Japan, but U.S. approval not likely until 2019
Fierce Pharma
Japan
Shionogi
Flu
influenza
Xofluza
Flag link:
Shionogi, Roche get their first approval for the next big thing in fighting the flu
Shionogi, Roche get their first approval for the next big thing in fighting the flu
Endpoints
Shionogi
Roche
Flu
influenza
Xofluza
Japan
Tamiflu
Flag link:
Japan-based Shionogi develops powerful drug to treat influenza
Japan-based Shionogi develops powerful drug to treat influenza
GoinPharma
Shionogi
influenza
Flag link:
Crestor Developer Sees Sales Doubling On Lower-Priced Drugs
Crestor Developer Sees Sales Doubling On Lower-Priced Drugs
Bloomberg
Crestor
drug pricing
Shionogi
Flag link:
The FDA issues warning letter to Shionogi over co-pay voucher
The FDA issues warning letter to Shionogi over co-pay voucher
Medical Marketing and Media
FDA
warnings
Shionogi
co-pay vouchers
Flag link:
Why ViiV Healthcare leads the pharma industry in corporate reputation
Why ViiV Healthcare leads the pharma industry in corporate reputation
BioPharma Dive
ViiV Healthcare
Pfizer
GSK
Shionogi
AbbVie
Lundbeck
Janssen
Novo Nordisk
Flag link:
Roche looks beyond Tamiflu, striking deal for Shionogi's flu fighter
Roche looks beyond Tamiflu, striking deal for Shionogi's flu fighter
Fierce Pharma
Roche
Tamiflu
Shionogi
Flu
Flag link:
Glaxo’s Best ‘Headache’ Remedy May Be Buying Stakes in Ventures
Glaxo’s Best ‘Headache’ Remedy May Be Buying Stakes in Ventures
Bloomberg
GSK
Advair
Pfizer
Shionogi
Novartis
Flag link:
AstraZeneca and Shionogi extend Crestor license
AstraZeneca and Shionogi extend Crestor license
Reuters
Crestor
AstraZeneca
Shionogi
Flag link:
Targeting An Untapped Female Sexual Dysfunction Drug Market
Targeting An Untapped Female Sexual Dysfunction Drug Market
Seeking Alpha
female sexual dysfunction
Osphena
Shionogi
flibanserin
Sprout Pharmaceuticals
bremelanotide
Palatin
Femprox
Apricus Biosciences
Flag link:
Can This HIV Drug Challenge Gilead's Domination?
Can This HIV Drug Challenge Gilead's Domination?
Motley Fool
Gilead
HIV
ViiV Healthcare
Tivicay
GSK
Shionogi
Pfizer
Flag link:
FDA Delivers a Double Dose of Good News in the Fight Against HIV
FDA Delivers a Double Dose of Good News in the Fight Against HIV
Motley Fool
FDA
HIV
Alere
Alere Determine
Tivicay
vaccines
ViiV Healthcare
GSK
Shionogi
Pfizer
Flag link:
ViiV Healthcare Partnership Anticipates New HIV Treatment Approval
ViiV Healthcare Partnership Anticipates New HIV Treatment Approval
Seeking Alpha
ViiV Healthcare
GSK
Pfizer
Shionogi
Dolutegravir
HIV
Flag link:
Common Drug Has The Potential To Slow Aging, Boost Cancer Recovery
Common Drug Has The Potential To Slow Aging, Boost Cancer Recovery
Forbes
metformin
Shionogi
Bristol-Myers Squibb
Santarus
Ranbaxy
Flag link:
GSK wins priority status for new HIV drug in U.S.
GSK wins priority status for new HIV drug in U.S.
Reuters
GSK
HIV
Shionogi
ViiV Healthcare
Dolutegravir
Flag link:
Shionogi applies for HIV drug approval in U.S., Europe
Shionogi applies for HIV drug approval in U.S., Europe
Reuters
Shionogi
HIV
FDA
Europe
Dolutegravir
ViiV Healthcare
Flag link:
Glaxo-Pfizer HIV Drug Helps Hard-to-Treat Patients
Glaxo-Pfizer HIV Drug Helps Hard-to-Treat Patients
Bloomberg
GSK
Pfizer
HIV
Dolutegravir
Shionogi
Flag link:
Shionogi enters into license agreement with Janssen for Alzheimer's treatment
Shionogi enters into license agreement with Janssen for Alzheimer's treatment
Equities.com
Shionogi
Janssen Pharmaceuticals
Alzheimer's disease
Flag link:
Shionogi to take 10 pct stake in GSK, Pfizer HIV drug venture
Shionogi to take 10 pct stake in GSK, Pfizer HIV drug venture
Reuters
Shionogi
GSK
Pfizer
HIV
Dolutegravir
Flag link:
Can These 3 Companies Take Down Gilead?
Can These 3 Companies Take Down Gilead?
Motley Fool
Gilead
HIV
ViiV Healthcare
Shionogi
Merck
Bristol-Myers Squibb
Flag link:

Pages